TITLE

Market watch: Upcoming market catalysts in Q3 2013

AUTHOR(S)
Roybal, Dane
PUB. DATE
July 2013
SOURCE
Nature Reviews Drug Discovery;Jul2013, Vol. 12 Issue 7, p496
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the growing market for catalysts in 2013. REGN727 is a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor from Regeneron, while Merck has developed suvorexant for insomnia. Information on the REGN727 clinical trials is provided. An advisory committee of the U.S. Food and Drug Administration voted positively on the safety of Merck's suvorexant. Positive results were obtained by Boehringer Ingelheim from its Phase III trial of afatinib.
ACCESSION #
88783762

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics